Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by State Street Corp

State Street Corp boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 4.2% in the 3rd quarter, Holdings Channel reports. The firm owned 6,627,320 shares of the company’s stock after acquiring an additional 269,274 shares during the quarter. State Street Corp’s holdings in Sana Biotechnology were worth $27,570,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stifel Financial Corp purchased a new position in Sana Biotechnology in the 3rd quarter worth approximately $43,000. Blue Trust Inc. lifted its position in Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after buying an additional 12,154 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new position in Sana Biotechnology during the third quarter worth approximately $67,000. Algert Global LLC purchased a new stake in Sana Biotechnology in the 2nd quarter valued at $73,000. Finally, XTX Topco Ltd purchased a new stake in Sana Biotechnology in the 2nd quarter valued at $100,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Up 3.1 %

NASDAQ:SANA opened at $1.65 on Monday. Sana Biotechnology, Inc. has a 52 week low of $1.55 and a 52 week high of $12.00. The stock’s fifty day moving average is $2.93 and its two-hundred day moving average is $4.49. The company has a market capitalization of $368.39 million, a P/E ratio of -1.18 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 31.10% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.